Clinical trial
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in…
NCT00071812 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00071812 |
|---|---|
| Title | A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) |
| Official title | A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg |
| Enrollment | 283 |
| Start date | Dec 1, 2003 |
| Primary completion | Jan 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Nov 5, 2003 |
| Last update posted | Aug 14, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: